SCHEMBL4697290

SCHEMBL4697290

Oc1cccc(OCc2ccc(Cl)cc2)c1

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.70
NR4A2 P43354 1/20 0.65
MAOB P27338 7/20 0.63
MAOA P21397 3/20 0.63
RXRA P19793 1/20 0.56
RXRB P28702 1/20 0.56
RXRG P48443 1/20 0.56
SMPD1 P17405 1/20 0.56
MEN1 O00255 1/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 1/20 0.52
KMT2A Q03164 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TLR4 O00206 1/20 0.52
TLR2 O60603 1/20 0.52
HPD P32754 1/20 0.52
SPHK2 Q9NRA0 1/20 0.51
SPHK1 Q9NYA1 1/20 0.51
F2 P00734 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31533129 1.00 APP (0.70) APPNR4A2MAOBMAOARXRA
SCHEMBL27735405 0.87 APP (0.77) APPMAOBMEN1KMT2AF2
SCHEMBL4699232 0.85 GPR84 (0.52) APPNR4A2MAOBMAOA
SCHEMBL4698486 0.84 NR4A2 (0.66) APPNR4A2MAOBMAOARXRA
SCHEMBL29548398 0.83 APP (0.71) APPNR4A2MAOBMAOASMPD1
SCHEMBL384725 0.83 APP (0.71) APPNR4A2MAOBMAOASMPD1
SCHEMBL11121827 0.83 SMN1; SMN2 (0.66) NR4A2MAOBMAOARXRARXRB
SCHEMBL22964317 0.82 MAOB (0.58) APPNR4A2MAOBMAOARXRA
SCHEMBL18429651 0.82 APP (1.00) APPMAOBRXRARXRBF2
SCHEMBL11300058 0.82 MAOB (0.70) APPNR4A2MAOBMAOAHPD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3828162-B1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES COMPRISING THE SAME AUTOTAC INC (KR) 2025-07-09 EP disclosed
US-11981618-B2 P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same AUTOTAC INC. (KR) 2024-05-14 US disclosed
US-20210347749-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME PROTECH CO., LTD. (KR) 2021-11-11 US disclosed
EP-3828162-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, ALLEVIATING, OR TREATING PROTEIN ABNORMALITY DISORDERS Protech Co., Ltd. (KR) 2021-06-02 EP disclosed
CN-112424159-A Novel P62 ligand compound and composition for preventing, ameliorating or treating protein conformational diseases comprising the same 普罗泰克株式会社 2021-02-26 CN disclosed
WO-2020022783-A9 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, ALLEVIATING, OR TREATING PROTEIN ABNORMALITY DISORDERS 주식회사 프로텍바이오 2020-03-19 WO disclosed
WO-2020022783-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, ALLEVIATING, OR TREATING PROTEIN ABNORMALITY DISORDERS 주식회사 프로텍바이오 2020-01-30 WO disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 US disclosed
EP-1926737-B1 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-03-15 EP disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 WO disclosed
CN-101263145-A 4-amino-thieno [3, 2-C ] pyridine-7-carboxylic acid derivatives HOFFMANN LA ROCHE (CH) 2008-09-10 CN disclosed
EP-1926737-A1 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-06-04 EP disclosed
WO-2007031428-A1 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-03-22 WO disclosed
WO-2007031428-A1 4-AMINO-THIENO[3,2-C]PYRIDINE-7-CARBOXYLIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-03-22 WO disclosed
US-20070060607-A1 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives BARTKOVITZ DAVID J 2007-03-15 US disclosed
US-20070060607-A1 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives BARTKOVITZ DAVID J 2007-03-15 US disclosed
US-20070060607-A1 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives BARTKOVITZ DAVID J 2007-03-15 US disclosed
US-4538164-A LEUCO DYE, HYDROXYPHENOLIC ETHER DEVELOPER, OIL ABSORBING FILLER RICOH CO., LTD. (JP) 1985-08-27 US disclosed
EP-0044536-A1 Plant growth regulators and their use J.T. Baker Chemical Co. (US) 1982-01-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210347749-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME SQSTM1, ATG7, BECN1 APP 201/4885NR4A2 1540/4885MAOB 4835/4885
US-20070060607-A1 4-amino-thieno[3,2-c] pyridine-7-carboxylic acid derivatives BRAF, RAF1, MAP3K7 APP 4741/4885NR4A2 1933/4885MAOB 1364/4885
US-11981618-B2 P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same SQSTM1, ATG7, BECN1 APP 142/4885NR4A2 1737/4885MAOB 4830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.